This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Both over expression of cyclic AMP response element binding protein (CREB) in the nucleus accumbens (NAc), and intra-accumbal injection of cocaine- and amphetamine-regulated transcript (CART) peptides, have been shown to decrease cocaine reward. Also, over expression of CREB in the rat NAc increased CART mRNA and peptide levels, but it is not known if this was due to a direct action of P-CREB on the CART gene promoter. The goal of this study was to test if CREB and P-CREB bound directly to the CRE site in the CART promoter, using chromatin immunoprecipitation (ChIP) assays. ChIP assay with anti-CREB antibodies showed an enrichment of the CART promoter fragment containing the CRE region over IgG precipitated material, a non-specific control. Forskolin, which was known to increase CART mRNA levels in GH3 cells, was utilized to show that the drug increased levels of P-CREB protein and P-CREB binding to the CART promoter CRE-containing region. A region of the c-Fos promoter containing a CRE cis-regulatory element was previously shown to bind P-CREB, and it was used here as a positive control. These data suggest that the effects of CREB over expression on blunting cocaine reward could be, at least in part, attributed to the increased expression of the CART gene by direct interaction of P-CREB with the CART promoter CRE site, rather than by some indirect action.
Public Health Relevance Statement
Data not available.
NIH Spending Category
Genetics
Project Terms
AntibodiesBindingBiological AssayCARTPT geneCellsCocaineCyclic AMP-Responsive DNA-Binding ProteinDataElementsFOS geneForskolinFundingGenesGlycine decarboxylaseGoalsGrantImmunoglobulin GInjection of therapeutic agentMessenger RNANational Center for Research ResourcesNucleus AccumbensPeptidesPharmaceutical PreparationsPrimatesPrincipal InvestigatorProtein BindingRattusRegulationRegulatory ElementResearchResearch InfrastructureResourcesRewardsSiteSourceTestingUnited States National Institutes of Healthchromatin immunoprecipitationcostpromoter
No Sub Projects information available for 2P51RR000165-51 7110
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2P51RR000165-51 7110
Patents
No Patents information available for 2P51RR000165-51 7110
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2P51RR000165-51 7110
Clinical Studies
No Clinical Studies information available for 2P51RR000165-51 7110
News and More
Related News Releases
No news release information available for 2P51RR000165-51 7110
History
No Historical information available for 2P51RR000165-51 7110
Similar Projects
No Similar Projects information available for 2P51RR000165-51 7110